Eli Lilly makes all Zepbound doses available in single-dose vials
Eli Lilly said it will make the two highest doses of its popular obesity drug Zepbound available to certain patients in cheaper, single-dose vials. The company first launched single-dose vial formulations for the two lowest …
GLP-1 Drugs May Help in Fibromyalgia, Large Records Study Suggests
(MedPage Today) — BARCELONA — A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel and possibly tectonic approach to treating fibromyalgia, her presentation here suggested. That experience…
Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?
Bardet-Biedl syndrome (BBS) is a complex genetic condition that can affect multiple organ systems, frequently causing pigmentary retinopathy, renal abnormalities, polydactyly, and obesity. Metabolic disturbances including obesity, unsuppressed appetite, and an increased risk of type 2 diabetes (T2D) present clinical management challenges. In this issue of the JCI, Singh et al. present a mouse model […]
V-type starch-galloyl-based polyphenol complex stimulates GLP-1 and PYY secretion and improves satiety in mice
Publication date: Available online 15 June 2025 Source: Carbohydrate Polymers Author(s): Yimei Zheng, Tonglin Chen, Ke Li, Liang Wang, Xuwei Liu, Lei Zhao, Zhuoyan Hu, Kai Wang
Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model
Bardet-Biedl syndrome (BBS), a ciliopathy characterized by obesity, hyperphagia, and learning deficits, arises from mutations in Bbs genes. Exacerbated symptoms occur with mutations in genes encoding the BBSome, a complex regulating primary cilia function. We investigated the mechanisms underlying BBS-induced obesity using a Bbs5-knockout (Bbs5–/–) mouse model. Bbs5–/– mice were characterized by hyperphagia, learning deficits, […]
GLP-1 Drugs and Liver Screening Took Center Stage at AACE Meeting
(MedPage Today) — At the recent American Association of Clinical Endocrinology (AACE) annual meeting, leaders highlighted major advances in endocrine care, particularly around obesity and metabolic liver disease. In this MedPage Today video…
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.
Wegovy and Mounjaro might affect how well your contraceptives work—here’s why
Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those trying to lose weight. But a rise in so-called “Ozempic babies” has led the UK’s medicines regulator to issue guidance on their use by women of reproductive age.
Lilly to Offer Highest Doses Of Weight-loss Drug Zepbound on Website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on… Reuters Health Information